Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online March 23, 2007
Diabetes Care 30:1880-1882, 2007
DOI: 10.2337/dc06-2257
© 2007 by the American Diabetes Association
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc06-2257v1
30/7/1880    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sirois, C.
Right arrow Articles by Grégoire, J.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sirois, C.
Right arrow Articles by Grégoire, J.-P.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Epidemiology/Health Services/Psychosocial Research
Brief Report

Suboptimal Use of Cardioprotective Drugs in Newly Treated Elderly Individuals With Type 2 Diabetes

Caroline Sirois, BPHARM, MSC1,2,3, Jocelyne Moisan, PHD1,2, Paul Poirier, MD, PHD1,4 and Jean-Pierre Grégoire, MPH, PHD1,2

1 Faculty of Pharmacy, Laval University, Quebec, Canada
2 Population Health Research Unit, Centre Hospitalier Affilié Universitaire de Québec, Quebec, Canada
3 Institut National de Santé Publique du Québec, Quebec, Canada
4 Quebec Heart Institute, Laval Hospital, Quebec, Canada

Address correspondence and reprint requests to Jean-Pierre Grégoire, Population Health Research Unit, Centre Hospitalier Affilié Universitaire de Québec, 1050, Chemin Sainte-Foy, Québec, Quebec City, Canada, G1S 4L8. E-mail: jean-pierre.gregoire{at}pha.ulaval.ca

Abbreviations: CCR, comprehensive cardioprotective regimen


   INTRODUCTION
TOP
 INTRODUCTION
RESEARCH DESIGN AND METHODS--
 RESULTS--
 CONCLUSIONS--
 References
 
Cardiovascular disease is the main complication experienced by elderly individuals with diabetes (1). Despite randomized trials showing the benefits of individual (2–4) or combined (5) pharmacological treatments of cardiovascular risk factors in diabetes, observational studies have shown suboptimal use of medications (6–8). However, little is known about the use of cardioprotective medication among elderly individuals who were not already taking it before diabetes treatment was undertaken. We therefore studied a population of elderly individuals with type 2 diabetes in the province of Quebec, Canada, who had not been treated with any antihypertensive, lipid-lowering, or antiplatelet drugs in the year before oral antidiabetes drug initiation. We assessed whether they used a comprehensive cardioprotective regimen (CCR) of those three medications in the year following oral antidiabetic initiation. We also identified the determinants of a CCR use.


   RESEARCH DESIGN AND METHODS—
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS--
RESULTS--
 CONCLUSIONS--
 References
 
We carried out a population-based inception cohort study using the Quebec Diabetes Surveillance System, which is the product of linking public health administrative databases managed by the Quebec Health Insurance Board. It includes information on patient demographics, physician and hospital services, and data from the public drug plan for individuals who had been diagnosed with diabetes.

We selected individuals aged ≥66 years who had initiated an oral antidiabetes medication treatment between 1 January 1998 and 31 December 2002. The date of the first claim was the index date. We excluded individuals who had received any insulin or oral antidiabetes, antiplatelet, antihypertensive, or lipid-lowering drugs during the 365 days before the index date. We also excluded those who had not been beneficiaries of the drug plan for the entire 365-day period before the index date and individuals who had not for at least 1 year of follow-up.

A person was deemed to have a CCR if there was at least one claim for each of the following: an antihypertensive, lipid-lowering, and antiplatelet drug in the year following the index date. Each of the three drugs could be used at different times during follow-up.

Potential determinants of CCR use included sex, age, and residential area of the individuals; year of oral antidiabetes agent initiation; and whether the oral antidiabetes therapy was initiated in the 14 days posthospitalization. Other potential determinants measured in the year before the index date were included: 1) number of outpatient medical visits, 2) hospitalization, and 3) cardiovascular disease.

The proportion of individuals using a CCR was calculated. Determinants of CCR use were identified using multivariate logistic regression. Odds ratios and their 99% CIs were calculated. Analyses were carried out using SAS, version 9.1.

This research was approved by the Commission d'accès à l'information du Québec and the Comité d'éthique à la Recherche du Centre Hospitalier Affilié Universitaire de Québec.


   RESULTS—
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS--
 RESULTS--
CONCLUSIONS--
 References
 
Among the 12,150 individuals included in the cohort, 2,649 (21.8%) received an antiplatelet drug, 4,813 (39.6%) received an antihypertensive drug, and 2,562 (21.1%) received a lipid-lowering drug in the year following the oral antidiabetes medication initiation. Only 882 (7.6%) individuals received a CCR.

In the multivariate analysis, three out of eight potential determinants of CCR use remained statistically significant at the {alpha} level of 0.01 (Table 1). An older age at oral antidiabetes medication therapy initiation was inversely associated with CCR use, whereas suffering from cardiovascular disease was positively associated with the use of a CCR. The odds of being exposed to a CCR also increased over the time period (3.5% in 1998, 3.8% in 1999, 7.3% in 2000, 10.4% in 2001, and 12.9% in 2002).


View this table:
[in this window]
[in a new window]

  		Table 1— Determinants of CCR* use among individuals who did not receive any cardioprotective drug in the year prior to antidiabetes treatment initiation (n = 12,150)

 

   CONCLUSIONS—
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS--
 RESULTS--
 CONCLUSIONS--
References
 
Among elderly individuals not exposed to cardiovascular drugs in the year before the initiation of oral antidiabetes medication therapy, the proportion of CCR users is low (7.6%). If diabetes is to be considered a cardiovascular equivalent (9), these results suggest that the management of cardiovascular risk for those patients is less than appropriate.

Other studies have demonstrated gaps in the use of cardiovascular risk–modifying drugs among elderly individuals with diabetes (10–11). Of 105,715 elderly individuals in Ontario, Canada, around two-thirds used antihypertensive agents and about one-quarter received a lipid-lowering drug in a period of 6 months following the 1st year of diabetes diagnosis (11).

A low proportion of the combined use of antiplatelet drugs, statins, and ACE inhibitors was also found in a cohort of individuals with various length and duration of diabetes in Saskatchewan, Canada (12). In that study, of 12,106 patients aged 30–105 years, 596 (5%) used the combined treatment (12).

Some of the factors associated with CCR use in our study have been observed by others. Younger type 2 diabetic patients (13) and those suffering from cardiovascular disease (14) were found to be more likely to obtain aggressive cardiovascular treatments. Improvement in use of cardiovascular drugs through recent years has been reported (8,15). On the other hand, it has been reported that women with diabetes were less likely than men to receive acetylsalicylic acid (14,16) or lipid-lowering drugs (17) or to have blood pressure and cholesterol levels below current targets (18). In our population of newly treated individuals, sex did not appear to influence the use of a CCR.

The unavailability of clinical data in the administrative data used represents a limitation of the study, making it difficult to evaluate individual appropriateness of CCR use. However, according to clinical guidelines, the majority of individuals would qualify for CCR use. Most elderly individuals require pharmaceutical agents to reach aggressive blood pressure (130/80 mmHg) and LDL cholesterol (2.6 mmol/l) targets (19,20). The vast majority of elderly individuals with diabetes should also be using ACE inhibitors or angiotensin receptor antagonists for vascular protection (21). Moreover, all individuals included in our study should have received an antiplatelet drug unless contraindicated (19,20).

All in all, this study indicates that initiating a new antidiabetes agent does not much influence the use of a CCR. Future studies should evaluate the underlying risk of patients with clinical information and assess whether a CCR is beneficial in terms of outcomes.


   Acknowledgments
 
C.S. was a recipient of Canada's Research-Based Pharmaceutical Companies (Rx&D) Health Research Foundation/Canadian Institute of Health Research graduate research scholarship and is a recipient of a scholarship from the Fonds de la Recherche en Santé du Québec (FRSQ). P.P. is a research scientist with the FRSQ.

The authors thank Danielle St-Laurent, Valérie Émond, and Louis Rochette from the Institut National de Santé Publique du Québec and Joanne Vidal for editing the manuscript.


   Footnotes
 
Published ahead of print at http://care.diabetesjournals.org on 20 March 2007. DOI: 10.2337/dc06-2257.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

Received for publication November 3, 2006. Accepted for publication March 14, 2007.


   References
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS--
 RESULTS--
 CONCLUSIONS--
 References
 

  1. Bertoni AG, Krop JS, Anderson GF, Brancati FL: Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care 25:471–475, 2002[Abstract/Free Full Text]
  2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145–153, 2000[Abstract/Free Full Text]
  3. Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005–2016, 2003[Medline]
  4. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755–1762, 1998[Medline]
  5. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393, 2003[Abstract/Free Full Text]
  6. Klinke JA, Johnson JA, Guirguis LM, Toth EL, Lee TK, Lewanczuk RZ, Majumdar SR: Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada. Clin Ther 26:439–446, 2004[Medline]
  7. Toth EL, Majumdar SR, Guiguis LM, Lewanczuk RZ, Lee TK, Johnson JA: Compliance with clinical practice guidelines for type 2 diabetes in rural patients: treatment gaps and opportunities for improvement. Pharmacotherapy 23:659–665, 2003[Medline]
  8. Saaddine JB, Cadwell B, Gregg EW, Engelgau MM, Vinicor F, Imperatore G, Narayan KM: Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. Ann Intern Med 144:465–474, 2006[Abstract/Free Full Text]
  9. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234, 1998[Abstract/Free Full Text]
  10. Emberson JR, Whincup PH, Lawlor DA, Montaner D, Ebrahim S: Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women. Heart 91:451–455, 2005[Abstract/Free Full Text]
  11. Shah BR, Huz JE, Laupacis A, Zinman B, Booth GL: Use of vascular risk-modifying medications for diabetic patients differs between physician specialties. Diabet Med 23:1117–1123, 2006[Medline]
  12. Brown CL, Johnson JA, Majumdar SR, Tsuyiki RT, McAlister AF: Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 171:1189–1192, 2004[Abstract/Free Full Text]
  13. Safford M, Eaton L, Hawley G, Brimacombe M, Rajan M, Li H, Pogach L: Disparities in use of lipid-lowering medications among people with type 2 diabetes mellitus. Arch Intern Med 163:922–938, 2003[Abstract/Free Full Text]
  14. Ferrara A, Williamson DF, Karter AJ, Thompson TJ, Kim C: Sex differences in quality of health care related to ischemic heart disease prevention in patients with diabetes: the translating research into action for Diabetes (TRIAD) study, 2000–2001. Diabetes Care 27:2974–2976, 2004[Free Full Text]
  15. Kopp A, Mamdani M, Shah BR: Drug use in older people with diabetes. In Diabetes in Ontario: An ICES Practice Atlas Booth GL, Hux JE, Laupacis A, Slaughter PM, Eds. Toronto, Institute for Clinical Evaluative Sciences, 2003, p. 3.51–53.75
  16. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E: Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 28:514–520, 2005[Abstract/Free Full Text]
  17. Nau DP, Mallya U: Sex disparity in the management of dyslipidemia among patients with type 2 diabetes mellitus in a managed care organization. Am J Manag Care 11:69–73, 2005[Medline]
  18. Petri A, de Lusignan S, Williams J, Chan T, Majeed A: Management of cardiovascular risk factors in people with diabetes in primary care: cross-sectional study. Public Health 120:654–663, 2006[Medline]
  19. Canadian Diabetes Association: Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 27(Suppl. 2):S1–S152, 2003
  20. American Diabetes Association: Standards of medical care in diabetes—2007 (Position Statement). Diabetes Care 30(Suppl. 1):S4–S41, 2007
  21. Rosen AB: Indications for and utilization of ACE inhibitors in older individuals with diabetes: findings from the National Health and Nutrition Examination Survey 1999–2002. J Gen Intern Med 4:315–319, 2006

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc06-2257v1
30/7/1880    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sirois, C.
Right arrow Articles by Grégoire, J.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sirois, C.
Right arrow Articles by Grégoire, J.-P.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum